首页> 外文OA文献 >Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases

【2h】

Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases

机译：临床候选LXE408的发现与表征作为对嗜血麦群岛治疗的运动蛋白选择性蛋白酶体抑制剂

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Advait Nagle; Agnes Biggart; Celine Be; Honnappa Srinivas; Andreas Hein; Diana Caridha; Richard J. Sciotti; Brandon Pybus; Mara Kreishman-Deitrick; Badry Bursulaya; Yin H. Lai; Mu-Yun Gao; Fang Liang; Casey J. N. Mathison; Xiaodong Liu; Vince Yeh; Jeffrey Smith; Isabelle Lerario; Yongping Xie; Donatella Chianelli; Michael Gibney; Ashley Berman; Yen-Liang Chen; Jan Jiricek; Lauren C. Davis; Xianzhong Liu; Jaime Ballard; Shilpi Khare; Fabian Kurt Eggimann; Alexandre Luneau; Todd Groessl; Michael Shapiro; Wendy Richmond; Kevin Johnson; Patrick J. Rudewicz; Srinivasa P. S. Rao; Christopher Thompson; Tove Tuntland; Glen Spraggon; Richard J. Glynne; Frantisek Supek; Christian Wiesmann; Valentina Molteni;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate [J] . Ramdas Vidya, Talwar Rashmi, Banerjee Moloy, Journal of Medicinal Chemistry . 2019,第23期

机译：含有新型三环中央核心的强化泛基因型HCV NS5A抑制剂的发现与表征，导致临床候选者
2. Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indo1-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate [J] . Crosignani Stefano, Bingham Patrick, Bottemanne Pauline, Journal of Medicinal Chemistry . 2017,第23期

机译：发现一种新颖和选择性吲哚胺2,3-二氧化根蛋白酶（IDO-1）抑制剂3-（5-氟-1H- Indo1-3-Y1）吡咯烷-2,5-二酮（EOS200271 / PF-06840003）及其表征作为潜在的临床候选人
3. Discovery and Characterization of Atropisomer PH-797804, a p38 MAP Kinase Inhibitor, as a Clinical Drug Candidate [J] . Li Xing, Balekudru Devadas, Rajesh V. Devraj ChemMedChem . 2012,第2期

机译：p38 MAP激酶抑制剂Atropisomer PH-797804的发现和表征，作为临床候选药物
4. Nonclinical Discovery and Development of Bortezomib (PS-341, VELCADE~(R)) a Proteasome Inhibitor for the Treatment of Cancer [C] . Bouchard PR, Juedes M, Nix D, Annual Meeting of the American Society for Veterinary Clinical Pathology . 2004

机译：Bortezomib（PS-341，Velcade〜（R）的非临床发现和发展）一种治疗癌症的蛋白酶体抑制剂
5. The Discovery and Characterization of Small Molecule 20s Proteasome Activators: Implications in Proteostasis Disorders [D] . Njomen, Evert. 2019

机译：小分子20S蛋白酶体活化剂的发现与表征：蛋白质障碍的影响
6. Discovery of Clinical Candidate BMS-906024: A PotentPan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors [O] . Ashvinikumar V. Gavai, *, Claude Quesnelle, 2015

机译：BMS-906024临床候选者的发现：有力泛缺口抑制剂治疗白血病和实体瘤
7. Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases [O] . -1

机译：临床候选LXE408的发现与表征作为对嗜血麦群岛治疗的运动蛋白选择性蛋白酶体抑制剂

Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases

著录项

引文网络

相似文献

相关主题

期刊订阅